Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 546

1.

Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.

Dell'Osso B, Allen A, Hollander E.

Expert Opin Pharmacother. 2005 Dec;6(15):2727-40. Review.

PMID:
16316311
2.

Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.

Piccinelli M, Pini S, Bellantuono C, Wilkinson G.

Br J Psychiatry. 1995 Apr;166(4):424-43.

PMID:
7795913
3.

Pharmacologic therapy of obsessive compulsive disorder.

DeVeaugh-Geiss J.

Adv Pharmacol. 1994;30:35-52. Review.

PMID:
7833296
4.

A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.

Milanfranchi A, Ravagli S, Lensi P, Marazziti D, Cassano GB.

Int Clin Psychopharmacol. 1997 May;12(3):131-6.

PMID:
9248868
5.
6.

Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.

Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS.

Arch Gen Psychiatry. 1990 Jun;47(6):577-85.

PMID:
2112374
7.

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.

Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC.

Arch Gen Psychiatry. 1995 Jan;52(1):53-60.

PMID:
7811162
8.

Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

Figgitt DP, McClellan KJ.

Drugs. 2000 Oct;60(4):925-54. Review.

PMID:
11085201
9.

Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions.

Goodman WK, Ward H, Kablinger A, Murphy T.

J Clin Psychiatry. 1997;58 Suppl 5:32-49. Review.

10.

Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine.

den Boer JA, Westenberg HG, De Leeuw AS, van Vliet IM.

Int Clin Psychopharmacol. 1995 Jan;9 Suppl 4:47-52.

PMID:
7622824
11.

A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.

Pigott TA, Seay SM.

J Clin Psychiatry. 1999 Feb;60(2):101-6. Review.

PMID:
10084636
12.

Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine.

Marazziti D, Pfanner C, Palego L, Gemignani A, Milanfranchi A, Ravagli S, Lensi P, Presta S, Cassano GB.

Pharmacopsychiatry. 1997 Nov;30(6):245-9.

PMID:
9442546
13.

An integrated approach to treatment of obsessive compulsive disorder.

Greist JH.

J Clin Psychiatry. 1992 Apr;53 Suppl:38-41. Review.

PMID:
1532963
14.

Beyond depression: citalopram for obsessive-compulsive disorder.

Pato MT.

Int Clin Psychopharmacol. 1999 May;14 Suppl 2:S19-26. Review.

PMID:
10471169
15.
16.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
17.

Long-term management of obsessive-compulsive disorder.

Montgomery SA.

Int Clin Psychopharmacol. 1996 Dec;11 Suppl 5:23-9. Review.

PMID:
9032001
18.

Obsessive-compulsive disorder: a new perspective in diagnosis and treatment.

Lydiard RB.

Int Clin Psychopharmacol. 1994 Jun;9 Suppl 3:33-7. Review.

PMID:
7963449
19.

Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study.

Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J.

Acta Psychiatr Scand. 1997 Nov;96(5):343-6.

PMID:
9395151
20.

Fluvoxamine: new indication. No progress in obsessive-compulsive disorder.

[No authors listed]

Prescrire Int. 2004 Oct;13(73):163-5.

PMID:
15499694

Supplemental Content

Support Center